Novartis launches late-stage COPD trial; Intercell and Boehringer ink vaccine development deal;

 @FierceBiotech: Stem cell study shows early promise for MS. Report | Follow @FierceBiotech 

 @JohnCFierce: Tiny Avexa has buried its HIV therapy, demolishing its share price and leaving it scrambling for a survival strategy.Article | Follow @JohnCFierce

> Austria's Intercell and Boehringer Ingelheim have struck a new pact to develop animal vaccines. Report

> Gilead Sciences has announced a $5 billion stock buyback plan. It's the second stock repurchase program this year. Story

> The Daily Mail reports that scientists have developed a new drug that can swiftly switch off the immune response that triggers Type 1 diabetes. Report

> GE Capital, Healthcare Financial Services today announced it has provided an $11.25 million credit facility to Pacira Pharmaceuticals. Pacira release

> Seattle-based Coronado Biosciences has nailed $7 million in equity and options. Story

> The FDA's Dermatology and Ophthalmology Drugs Advisory Committee will review Lux Biosciences' new drug application for voclosporin on June 28. Release

> Cedra, a division of Worldwide Clinical Trials, named Anthony G. Busa, Jr., as its new CEO. Cedra release

And Finally... The start-up Pathway Genetics is planning to start marketing its genetic tests at retail outlets in the U.S. Article

Suggested Articles

After delivering a "positive surprise" in December, Biogen is painting a fuller picture of its lupus drug.

A new CRISPR technique neutralizes SARS-CoV-2 by scrambling the virus' genetic code. It could prove useful for fighting other viruses, like influenza.

The deal, which follows a bidding war with AcelRx, gives Melinta another approved antibiotic and potentially complementary R&D expertise.